Loading organizations...
§ Private Profile · San Francisco, CA, USA
Medical technology company developing AI-guided autonomous surgical robots for surgeons and hospitals, focused on endourology.
Key people at Andromeda Surgical.
Andromeda Surgical was founded in 2023 by Kartik Tiwari (Founder) and Nick Damiano (Founder).
Based in South San Francisco, California, Andromeda Surgical develops artificial intelligence-guided autonomous surgical robots and software designed to assist medical teams during endourology procedures. The company's platform focuses on natural orifice surgeries, specifically targeting prostate enucleation treatments by integrating advanced robotics with existing operating room tools to improve surgical precision. Operating with a team of 10 employees, the medical technology firm has generated $1.5 million in revenue and secured $500,000 in early funding. Andromeda Surgical is backed by notable investors including Y Combinator and WestWave Capital, and has established strategic clinical development partnerships with medical device manufacturers Richard Wolf and Quanta System. The enterprise recently facilitated the first robotic-assisted prostate enucleation procedure at Universidad Católica in Chile as it prepares for broader multi-specialty clinical trials. Andromeda Surgical was founded in 2023 by Nick Damiano and Kartik Tiwari.
Andromeda Surgical was founded in 2023 by Kartik Tiwari (Founder) and Nick Damiano (Founder).
Key people at Andromeda Surgical.
Andromeda Surgical is a South San Francisco-based startup developing autonomous surgical robots designed to democratize access to world-class surgical outcomes.[1][2] Founded in 2023, the company is tackling a fundamental challenge in modern medicine: surgical outcomes are constrained by individual surgeon skill and experience, creating vast disparities in patient care quality across geographies and economic strata.[1][3] The company's initial focus is on endourology procedures, specifically robotic-assisted HoLEP (holmium laser enucleation of the prostate) for treating benign prostatic hyperplasia—a condition affecting nearly 40 million men in the United States and over 500 million globally.[3] Rather than building surgical robots from scratch, Andromeda employs a software-first strategy, using off-the-shelf robotic arms paired with proprietary AI-driven localization and navigation systems to guide surgeons through complex procedures with minimal training.[1][3] The company has achieved remarkable speed-to-market, progressing from concept to first clinical procedure in just 18 months, with the world's first robotic-assisted HoLEP procedure completed in 2024.[2]
Andromeda Surgical was founded by Nick Damiano and Kartik Tiwari, both experienced serial entrepreneurs with deep roots in the Y Combinator ecosystem.[3] The founding team combines expertise spanning medtech, autonomous vehicles, and robotics—a pedigree that directly informs their approach to surgical automation.[1][2] Rather than pursuing the traditional path of building mechanically complex multi-port laparoscopic systems like market leader Intuitive Surgical (valued at $108 billion), Damiano and Tiwari identified an underserved niche: natural orifice procedures with steep learning curves but algorithmically simple mechanics.[1] The insight was elegant—procedures like HoLEP are mechanically straightforward but cognitively demanding, requiring surgeons to maintain precise spatial orientation while performing delicate maneuvers. This created a perfect use case for AI-augmented guidance systems rather than pure mechanical automation.
The company's breakthrough came through collaboration with Prof. Peter Gilling, one of HoLEP's original developers and a leading global urologist, who serves as lead principal investigator for Andromeda's clinical validation study (ASTRA).[2] This partnership provided both clinical credibility and real-world validation that the problem was worth solving at scale. The fact that Andromeda built a functional robotic platform in just three months—a remarkable feat in hardware development—demonstrates the founders' ability to execute with discipline and focus.[1]
Unlike traditional surgical robotics companies that compete primarily on mechanical precision and ergonomics, Andromeda inverts the value chain by leveraging commodity hardware (off-the-shelf robotic arms) and embedding intelligence in software.[1][3] This approach dramatically reduces capital requirements, accelerates time-to-market, and allows the company to iterate rapidly on AI capabilities without hardware redesigns.
The company's core innovation is a GPS-like localization system that helps surgeons maintain precise spatial awareness during procedures.[1] Rather than replacing surgeon judgment, Andromeda augments it—the AI handles the cognitively taxing work of real-time orientation and navigation, allowing surgeons to focus on decision-making and technique. This human-in-the-loop model is fundamentally different from fully autonomous surgical systems and addresses regulatory, liability, and adoption concerns more elegantly.
HoLEP has been the gold-standard treatment for enlarged prostate since 1998 but has seen limited adoption precisely because it requires extensive training to master.[2] By reducing this learning curve, Andromeda unlocks a massive addressable market—most urologists currently cannot perform the procedure at expert level, creating artificial scarcity in access to optimal outcomes.
Building a functional robotic platform in three months is exceptional in an industry where hardware development typically spans years.[1] This speed reflects both the founders' autonomous vehicle background (where rapid iteration is standard) and their deliberate choice to avoid mechanical complexity by targeting natural orifice procedures.
Andromeda sits at the intersection of three powerful macro trends: the AI revolution, the robotics renaissance, and the healthcare cost crisis. The surgical robotics market is already substantial—Intuitive Surgical's $108 billion valuation reflects decades of value creation—but it remains concentrated in a narrow set of procedures and geographies.[1] The broader market for surgical robots exceeds $150 billion, yet most of this value is locked behind high barriers to entry (capital intensity, regulatory complexity, surgeon training requirements).[3]
Andromeda's timing is optimal because large language models and computer vision systems have matured to the point where real-time surgical guidance is now feasible. The company is riding the wave of AI commoditization—what would have required years of custom development five years ago can now be built in months using foundation models and modern ML infrastructure. Simultaneously, healthcare systems globally face mounting pressure to improve outcomes while controlling costs, making any technology that democratizes access to expert-level care inherently valuable.
The company also benefits from a favorable regulatory environment. The FDA has established clear pathways for AI-assisted surgical devices, and the clinical validation of HoLEP as a gold-standard procedure means Andromeda is not fighting to establish efficacy—only to prove that robotic assistance maintains or improves upon existing outcomes. This de-risks the regulatory journey considerably compared to novel surgical approaches.
Andromeda Surgical represents a compelling thesis: the next wave of surgical robotics will not be won by companies that build the most mechanically sophisticated systems, but by those that most effectively augment surgeon cognition through AI. The company's software-first model, lean execution, and focus on high-volume procedures with clear unmet needs position it well to capture significant market share in endourology and expand into adjacent specialties.
The immediate roadmap involves scaling the ASTRA clinical trial (beginning enrollment in New Zealand in early 2025) to establish clinical evidence, then expanding HoLEP adoption globally.[2] The company's stated vision extends far beyond prostate procedures—the long-term ambition is to enhance all surgeons' abilities across a broad range of procedures, representing a $10 billion+ opportunity in urology alone and substantially more across all surgical specialties.[3]
The key inflection points to watch are: (1) clinical trial results demonstrating that robotic-assisted HoLEP reduces learning curves and improves outcomes, (2) regulatory clearance in major markets beyond New Zealand, and (3) evidence of adoption velocity among urologists. If Andromeda can prove that AI-guided surgery meaningfully improves outcomes while reducing training burden, the company could catalyze a fundamental shift in how surgical robotics are designed and deployed—moving from mechanical precision as the primary value driver to cognitive augmentation as the core differentiator. In a healthcare system desperate for solutions that improve quality while controlling costs, that shift could be transformative.
